Skip to main content
TipRanks
Go Ultimate75% OFF

Pure Bioscience (PURE) AI Stock Analysis

47 Followers
PURE

Pure Bioscience

(Other OTC:PURE)

Select Model
Rating:38Underperform
Price Target:$0.05â–¼(-12.73% Downside)
Action:downgraded
Date:11/20/26

The overall score of 38 reflects a company in severe financial distress. The dominant factor is the dire financial performance, marked by insolvency, massive unprofitability, and persistent cash burn. While a recent insider-led financing event shows a sliver of support, it is a small, dilutive measure against overwhelming fundamental risks. The stock's deeply bearish technical trend and meaningless valuation metrics further confirm the high-risk profile.

Positive Factors
Proprietary Antimicrobial PlatformA proprietary silver-based antimicrobial platform gives PURE a defined product foundation across food safety, surface disinfection, and hygiene applications. This breadth can support continued product development and commercialization across multiple commercial and industrial use cases over time.
Negative Factors
Negative Equity and Rising LeverageDeeply negative equity and rising leverage weaken financial resilience and reduce flexibility to fund operations or absorb setbacks. They also increase dependence on refinancing or additional equity issuance, creating continuing solvency and dilution risks over the next several quarters.

Pure Bioscience (PURE) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%PURE+17.02%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.15M
Dividend Yield
―
Average Volume (3M)
29.56K
Price to Earnings (P/E)
-2.6
Beta (1Y)
0.26
Revenue Growth
5.27%
EPS Growth
-0.47%
Country
US
Employees
11
Sector
Consumer Defensive
Sector Strength
62
Industry
Chemicals

Pure Bioscience Business Overview & Revenue Model

Company Description

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform co...

Pure Bioscience Financial Statement Overview

Summary

Financial health is critically weak. The company is deeply unprofitable with net losses exceeding revenue, has negative stockholders' equity indicating insolvency, and consistently burns cash from operations. The only minor positive is a gross margin above 57%, but this is overwhelmed by existential balance sheet risks.

Income Statement

18Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJul 2026Jul 2025Jul 2024Jul 2023Jul 2022
Income Statement
Total Revenue2.32M2.32M2.20M1.96M1.88M1.85M
Gross Profit1.33M1.33M1.30M1.15M971.00K1.00M
EBITDA-2.07M-2.08M-2.10M-3.05M-3.83M-3.27M
Net Income-2.48M-2.48M-2.40M-3.35M-3.96M-3.50M
Balance Sheet
Total Assets1.19M1.19M1.06M818.00K1.82M4.48M
Cash, Cash Equivalents and Short-Term Investments569.00K569.00K334.00M349.00K1.09M3.39M
Total Debt6.60M6.60M523.60K2.95M1.02M0
Total Liabilities7.59M7.59M6.17M3.68M1.55M575.00K
Stockholders Equity-6.40M-6.40M-5.12M-2.86M272.00K3.91M
Cash Flow
Free Cash Flow-1.74M-1.74M-2.02M-2.53M-3.31M-2.50M
Operating Cash Flow-1.74M-1.74M-2.02M-2.53M-3.28M-2.42M
Investing Cash Flow0000-33.00K-81.00K
Financing Cash Flow1.97M1.97M2.00M1.78M1.01M3.50M

Pure Bioscience Technical Analysis

Technical Analysis SentimentNegative
Last Price0.06

Price Trends

50DMA0.07Negative
100DMA0.07Negative
200DMA0.07Negative

Market Momentum

MACD-0.00Positive
RSI45.81Neutral
STOCH33.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.81 is Neutral, neither overbought nor oversold. The STOCH value of 33.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PURE.

Pure Bioscience Risk Analysis

Pure Bioscience disclosed 39 risk factors in its most recent earnings report. Pure Bioscience reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.We have limited capital and will need to raise additional capital in the future.Q2, 2025

Pure Bioscience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

PURE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UGUG80Outperform$33.77M10.8127.84%7.48%23.63%59.59%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TANHTANH49Neutral$27.07M-98.09-24.71%―-10.67%-83.85%
TKLFTKLF43Neutral$5.84M0.811.71%14.77%77.22%-89.32%
GROVGROV42Neutral$33.45M-6.72-247.04%―-15.92%80.74%
PUREPURE38Underperform$7.71M-2.5741.29%―5.27%-0.47%
MTEXMTEX37Underperform$4.94M-8.2616.12%―-6.65%64.09%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%100%PUREMTEXUGTANHGROVTKLFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PURE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PUREPure Bioscience0.060.0117.02%
MTEXMannatech Inc2.56-7.28-73.98%
UGUnited-guardian7.352.1340.67%
TANHTantech Holdings Ltd.40.55-12.95-24.21%
GROVGrove Collaborative Holdings, Inc.0.78-0.60-43.62%
TKLFYoshitsu Co. Ltd. Sponsored ADR1.38-1.34-49.26%

Pure Bioscience Corporate Events

Business Operations and StrategyPrivate Placements and Financing

PURE Bioscience completes insider-led private equity financing

Positive
Oct 20, 2026

On October 15, 2026, PURE Bioscience, Inc. completed a private placement financing with accredited investors, raising $555,000 through the issuance of 10,183,486 shares of common stock at $0.0545 per share. Board member Tom Y. Lee provided the full f...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026